Eculizumab biosimilar is under clinical development by ISU ABXIS and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase I drugs for Autoimmune Disorders have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Eculizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Eculizumab biosimilar overview

Eculizumab biosimilar is under development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical haemolytic uraemic syndromen (aHUS) and autoimmune disorders. ISU-305 is administered through intravenous route. The therapeutic candidate is an antibody acts by targeting terminal complement protein C5.

ISU ABXIS overview

ISU ABXIS, a subsidiary of ISU Chemical Co Ltd, is a biotechnology company focused on the development of engineered antibody-based immunotherapies. The company’s pipeline products include ISU104 for head and neck cancer, colorectal cancer and breast cancer; ISU104 CAR-NK which treats leukemia, solid tumors; ABX2001 treats solid tumors; ABX2001 for hemophilia B; ISU305 treats paroxysmal nocturnal hemoglobinuria (PNH) and other autoimmune diseases; ISU203 for dementia by Alzheimer’s disease. It also offers fabagal, abcertin and clotinab. The company’s products are used by patients and healthcare providers in the medical industry, particularly in oncology and rare disease treatment. ISU ABXIS is headquartered in Seongnam, South Korea.

For a complete picture of Eculizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.